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ABSTRACT 
Background: About 5% of the bile acids (BAs) escape enterohepatic recirculation in the 
terminal ileum and enter the large intestine where they are further metabolized by the colonic 
microbiota and finally excreted in faeces. The amount and composition of faecal bile acids has 
been associated to several disease states. 
Aim: to develop a Gas Chromatography – Mass Spectrometry (GC-MS) based method 
that allows the quantification of bile acids (BA) in faecal samples and to validate this method.  
Methods: BAs were esterified and silylated to increase their volatility. Standard 
solutions of cholic acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), litocholic 
acid (LCA) and usodeoxycholic acid (UDCA) were prepared and used to optimize 
chromatographic parameters using hyodeoxycholic acid (HDCA) as internal standard. After 
optimizing the esterification (type of catalyst, temperature and time) and silylation (type and 
amount of reagent, temperature and time) the optimised method was validated. Intraday and 
interday precision and accuracy of calibration points was assessed as well as the limit of 
detection (LOD) and limit of quantification (LOQ). Similarly, precision and accuracy were 
determined for freeze dried stool samples and dried faecal water.  
Results: Baseline separation of the 5 BAs and internal standard was achieved on an 
apolar Rxi-1MS column with split injection (split flow 0.25 ml/min) using a He-flow of 
1.5 ml/min. Esterification was optimal using HCl 12N as catalyst and heating for 2 h at 60°C 
whereas the best conditions for silylation were 100 µl of HMDS+TMCS+Pyridine (3:1:9) and 
heating for 30 min at 55°C. The intraday and interday precision and accuracy was evaluated 
for each BA and concentration. LOD was 0.05 µg and LOQ was 0.1 µg for most BAs. However, 
for faecal samples, precision and accuracy were low, despite an additional sonication step and 
reflux in ethanol to improve the solubilisation of the BAs.  
Conclusions: Although the performance of the developed method was satisfying for BA 
standard solutions, its application to faecal samples needs further optimization of the clean -up 
of the samples prior to derivatisation. 
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RESUMO 
Background: Cerca de 5% dos ácidos biliares escapa à recirculação enterohepática 
no íleo terminal e entra no intestino grosso onde eles são posteriormente metabolizados  
pelo microbioma colónico e finalmente excretado nas fezes. A quantidade e composição 
dos ácidos biliares fecais tem sido associada a vários estados de doenças.  
Objetivo: desenvolver um método baseado em cromatografia gasosa — 
espectrometria de massa que permita a quantificação de ácidos biliares em amostras fecais 
e validar este mesmo método. 
Métodos: Os ácidos biliares foram esterificados e sililados para aumentar a sua 
volatilidade. Soluções padrão de ácido cólico, ácido desoxicólico, ácido quenodesoxicólico, 
ácido litocólico, ácido ursodesoxicólico foram preparadas e usadas para otimizar 
parâmetros cromatográficos, usando o ácido hiodesoxicólico como padrão interno. Após a 
otimização da esterificação (tipo de catalisador, temperatura e tempo) e sililação (tipo e 
quantidade de reagente, temperatura e tempo), o método otimizado foi validado. A precisão 
intra-dia e inter-dia e a exatidão dos pontos de calibração foram avaliadas bem como o 
limite de deteção e o limite de quantificação. Semelhantemente, a precisão e exatidão 
foram determinadas para amostras de fezes liofilizadas e para água fecal liofilizada.  
Resultados: A separação da linha de base dos 5 ácidos biliares e do padrão interno 
foi atingida com a coluna apolar Rxi-1MS com injeção em modo split (fluxo do split 0.25 
ml/min) usado com fluxo de He a 1.5 ml/min. A esterificação foi ótima usando HCl 12N 
como catalisador a uma temperatura de 60°C, durante 2 h, enquanto que as melhores 
condições para a sililação foram 100 µl de HMDS+TMCS+Pyridine (3:1:9) a uma 
temperatura de 55°C, durante 30 min. A precisão, intra- e inter-dia, e a exatidão foram 
avaliadas para cada ácido biliar e cada concentração. O limite de deteção foi 0.05 µg e o 
limite de quantificação foi 0.1 µg para a maioria dos ácidos biliares. Contudo, para as 
amostras fecais, a precisão e exatidão foram baixas, apesar do passo adicional da 
sonicação e refluxo em etanol para melhorar a solubilização dos ácidos biliares.  
Conclusões: Apesar do desempenho do método desenvolvido ter sido satisfeito para 
as soluções padrão dos ácidos biliares, a aplicação para as amostras fecais necessita 
posteriormente de uma otimização na limpeza das amostras antes da derivatização.  
Desenvolvimento e validação de um método baseado em GC-MS 
para analisar ácidos biliares fecais 
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1.1. GUT MICROBIOME 
 
The gut microbiome consists of an aggregate genome of trillions of microorganisms 
residing in the human gastrointestinal (GI) ecosystem (Ghaisas, Maher, & Kanthasamy, 
2016). 
Forbes and co-workers (2016), defined the term “microbiota” as “the population of 
microbes at a particular anatomical niche” and “microbiome” as “the collective genes 
encoded by all microbes of that particular niche”. 
In the healthy human gut most bacteria belong to four predominant bacterial phyla: 
Bacteroidetes, Firmicutes, Actinobacteria, and Proteobacteria (Tap et al., 2009).The 
phylum Bacteroidetes represents one of the most abundant genera in the gut (Huttenhower 
et al., 2012). 
Some studies revealed that the gut composition is influenced by several host 
factors, including quantity and quality of diet, lifestyle, use of antibiotics, and genetic 
background (Sanduzzi Zamparelli et al., 2016). Nevertheless, even with this diversity in 
microbial composition, recent studies revealed that the functional part of the healthy 
microbiome is relatively stable (Forbes, Van Domselaar, & Bernstein, 2016). 
For quite a long time, it has been thought that the development of the GI microbiota 
only started at birth, with exposure of the infant to its mother’s microbiota in the birth canal 
or to the mother’s skin in case of caesarean section. However, very recent studies reported 
that, already in utero, microbes pass from the mother to the foetus through the placenta 
(Sanduzzi Zamparelli et al., 2016). After weaning, the composition of the microbiota 
becomes more diverse and more stable and resembles that in adulthood (Claesson et al., 
2012). With ageing, numbers of bifidobacteria decline. 
Within the GI tract, both the numbers and the diversity of bacteria increase from 
the stomach to the colon, with the terminal ileum being the site where prevalent species 
change from aerobes to anaerobes (Mondot, de Wouters, Doré, & Lepage, 2013). The colon 
harbours the densest microbial population with up to 1012 cfu/g. In addition, microbial 
populations on mucosal surfaces significantly differ from that in the lumen (Li et al., 2015). 
Microbes at the mucosa surface are closer to the intestinal epithelium, and may have a 
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greater inﬂuence on the immune system whereas luminal microbes might be more crucial 
for energy and metabolic interactions. As a consequence, studies of the gut microbiota that 
use faecal material may not reflect the totality of viable microbes, and do not provide a 
complete overview of the portfolio of microbes (Forbes et al., 2016). 
The association between the gut microbiome and host immunity implicates a 
bidirectional correlation between microbes and the host innate and adaptive immune 
system. The balance between pro- and anti-inﬂammatory mechanisms is critical for gut 
immune homeostasis and is directly aﬀected by the commensal microbial communities of 
the gut (Forbes et al., 2016). 
Disturbance of the gut microbiome not only affects intestinal diseases, such as 
colorectal cancer (CLC), ulcerative colitis (UC) and inflammatory bowel disease (IBD), but 
also more systemic diseases such as diabetes, metabolic syndrome, atopy and cystic 
fibrosis (Aries, Crowther, Drasar, Hill, & Williams, 1969; Degirolamo, Modica, Palasciano, 
& Moschetta, 2011; Ghaisas et al., 2016; M. J. Hill et al., 1975; Walkera & Lawley, 2013) . 
Furthermore, the gut microbiome has been implicated in various type-2 diabetes 
(T2D)-related complications, including diabetic retinopathy, kidney toxicity, atherosclerosis, 
hypertension and diabetic foot ulcers (Zhang & Zhang, 2013). Also patients with celiac 
disease, have been shown to display GI microbiome abnormalities compared with healthy 
individuals (Fujimura & Slusher, 2010; Nadal, Donant, Ribes-Koninckx, Calabuig, & Sanz, 
2007). Besides, disturbance of the gut microbiome can also be related to central nervous 
system (CNS) disorders, such as Parkinson's and Alzheimer's diseases and autism (Ghaisas 
et al., 2016). Also autoimmune disorders such as lupus, multiple sclerosis, psoriasis, 
rheumatoid arthritis, the allergic disorders and asthma have been associated with 
aberrations in the human gut microbiome (Fujimura & Slusher, 2010). 
As a consequence, the gut microbiota has become an important target for 
promoting health, longevity, and potentially revolutionize the treatment of some diseases. 
Modulation of the microbiota can be achieved with interventions with prebiotics, probiotics 
or antibiotics. Management of the gut microbiome holds considerable potential in the 
domain of preventive medicine, having as the biggest challenge to control external factors 
as environmental and dietary influences, and to better understand genomic interactions 
between the host and the gut microbiome (Ghaisas et al., 2016). 
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Dysbiosis occurs when pathological imbalances in gut bacterial colonies precipitate 
disease and has been linked to the dysmetabolism of bile acids (BAs) in the gut (Sagar, 
Cree, Covington, & Arasaradnam, 2015). 
 
1.2. BILE ACIDS 
 
Bile acids (BAs) are synthesized from cholesterol in the liver and their production is 
the primary pathway for cholesterol catabolism. This conversion occurs exclusively in 
hepatocytes by a cascade of 12 reactions catalysed by different enzymes (Chiang, 2002). 
All BAs contain the same apolar sterol core structure that is substituted with 
hydroxyl groups at different positions and have a side chain that ends in a polar carboxyl 
group, Figure 1.1 (Humbert et al., 2012). These amphipathic nature of BAs is crucial to the 
function that they execute which is to facilitate solubilisation of lipids and their further 
absorption in the gastrointestinal tract. As amphipathic molecules, BAs also have powerful 
detergent properties (Houten, Watanabe, & Auwerx, 2006).  
 
 
Figure 1.1. General chemical structure of BAs (adapted from Humbert et al., 2012) 
 
Bile acids are synthesised in the liver and stored in the gallbladder. The BAs are 
conjugated with glycine or taurine to decrease their toxicity and increase solubility for 
secretion into bile (Degirolamo et al., 2011). After a meal, they flow into the duodenum and 
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intestine. Per day, between 0.2g to 0.6g of BAs is synthesised and secreted in healthy 
humans and on average 0.5g is excreted in faeces. It is estimated that 95% of BAs are 
reabsorbed from the gastrointestinal tract into the circulation, mainly via active transport in 
the terminal ileum through the apical sodium-dependent bile acid transporter (ASBT). A 
small amount is reabsorbed by passive diffusion in the upper intestine to the portal blood 
and is recycled to the liver. The same ASBT is present in the kidneys and prevents urinary 
excretion of bile acids that have undergone glomerular filtration (Cai & Chen, 2014; Chiang, 
2013; Houten et al., 2006). 
BAs that have been reabsorbed are transported to the liver via the portal blood and 
are taken up at the basolateral (sinusoidal) membrane and exported again at the apical 
(canalicular) membrane of the hepatocytes into the bile canaliculus (transhepatic BA ﬂux) 
(Houten et al., 2006). This cycle is known as the enterohepatic recirculation of BAs (Figure 
1.2). On average, BAs are recycled 4 to 12 times a day (Houten et al., 2006). The 
enterohepatic circulation of BAs is an important circuit not only for regulation of BAs 
synthesis, cholesterol homeostasis and absorption of nutrients, but also for the regulation 
of whole-body lipid metabolism (Chiang, 2009). 
 
 
Figure 1.2. Entheropatic Circulation of BAs (adapted from Chiang, 2013) 
  
 
Approximately 5% of BAs escapes reabsorption, and enters the colon where the BAs 
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undergo modifications by the intestinal microbiota (Batta et al., 1999). The glycine or 
taurine conjugates are hydrolysed by bacterial bile salt hydrolyses. The primary bile acids 
are converted into secondary bile acids by removal of the hydroxyl group on the 7α-position 
by bacterial enzymes (Cai & Chen, 2014). In this way CA is converted to DCA and CDCA is 
converted to LCA. CDCA can also be converted to other secondary BAs, including HCA, 
UDCA, MDCA, and others (Chiang, 2009; Li & Chiang, 2015). The UDCA, in humans, is 
not epimerised during the hepatocyte transport, being found in few percentage in the biliary 
bile acids in majority of people. (Hofmann & Hagey, 2008; Humbert et al., 2012) 
Besides their role in the absorption, transport, and distribution of lipid soluble 
vitamins and dietary fats, BAs also regulate bile acid and cholesterol metabolism, through 
signalling molecules that activate nuclear receptors such as the farnesol X receptor (FXR). 
In addition, BAs induce the cytochrome P450 3A (CYP3A) family of cytochrome P450 
enzymes that allow the detoxification of bile acids, drugs and xenobiotics in the liver and 
intestine, and also promote hepatocyte apoptosis (Chiang, 2002, 2009; Monte, Marin, 
Antelo, & Vazquez-Tato, 2009). Furthermore, BAs are also known to facilitate intestinal 
calcium absorption and to modulate pancreatic enzyme secretion (Koop et al., 1996; Monte 
et al., 2009). 
The BAs toxicity is determined by hydrophobicity which depends on the number, 
position and orientation (stereochemistry) of the hydroxyl groups. UDCA is the most 
hydrophilic and LCA is the most hydrophobic BA (magnitude of hydrophobic BAs: 
UDCA<CA<CDCA< DCA<LCA). The BAs hydrophobicity are linked to their intrinsic toxicity, 
with the more hydrophobic BAs being more toxic (Degirolamo et al., 2011). 
In healthy humans, secreted BAs, are composed of about 30% to 40% of CA, 
30% to 40% of CDCA, 20% to 30% of DCA, and a trace amount of LCA (Ajouz, Mukherji, & 
Shamseddine, 2014; Chiang, 2013). 
Diet composition, in particular high fat intake, has repeatedly been shown to 
influence the levels and composition of BAs in the colon, which explains the relevance of 
the analysis of faecal BAs in metabolic diseases, such as obesity, type 2 diabetes or 
hyperlipidaemia (M. J. Hill et al., 1975; Houten et al., 2006; Thomas, Pellicciari, Pruzanski, 
Auwerx, & Schoonjans, 2008). 
In patients with cirrhosis faecal DCA and LCA (secondary BAs) concentrations were 
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significantly lower than in control subjects. This same study (G Kakiyama et al., 2013) 
showed that the primary BAs were higher in advanced cirrhotics and secondary BAs were 
lower, suggesting that there is an association with cirrhosis and the decrease of conversion 
of primary to secondary BAs. 
Recent studies revealed an increase in primary BAs and a decrease in secondary 
BAs in IBD and IBS patients compared with healthy controls (Bajor, Törnblom, Rudling, 
Ung, & Simrén, 2015; Duboc et al., 2012; Slattery, Niaz, Aziz, Ford, & Farmer, 2015) . 
The secondary BAs levels are considered as cytotoxic and genotoxic and have been 
related with several disorders and diseases. The role of BAs in colorectal cancer risk and 
the mechanism of their effect have been the subject of many studies in this field 
(Degirolamo et al., 2011; Pearson, Gill, & Rowland, 2009). Actually, it is known that 
secondary BAs increase proliferation of colonic cells (Ochsenkühn et al., 1999), and induce 
apoptosis, being necessary to prevent mutated cells replicating for the futu re generations 
(Bernstein et al., 1999). 
Bile acids can also induce DNA damage, as DNA breaks were reported to directly 
correlate with bile acid concentrations (Venturi, Hambly, Glinghammar, Rafter, & Rowland, 
1997). Secondary, but not primary, BAs have recently been shown to exert adverse effects 
on epithelial barrier function, an endpoint thought to be related to tumour promotion 
(Hughes, Kurth, McGilligan, McGlynn, & Rowland, 2008). Significant evidence suggests that 
increased concentrations of DCA may be associated with colon polyp formation and large 
bowel cancer, acting as co-carcinogen in colon cancer (Batta et al., 1999). 
 
1.3. GAS CHROMATOGRAPHY-MASS SPECTROMETRY 
1.3.1. GAS CHROMATOGRAPHY 
Chromatography is a technique that separates compounds in a mixture, while they 
are transported by a mobile phase over a stationary phase. For gas chromatography (GC), 
the mobile phase is an inert gas, which transports the analyte of interest but does not 
interact with it. The stationary phase can either be a microscopic layer of a liquid on a solid 
support, called gas-liquid chromatography, or a solid, called gas-solid chromatography 
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(Neves, 1980; Skoog, Holler, & Nieman, 1997). In gas-liquid chromatography, which is the 
most commonly used type of GC, separation of the compounds is based on differences in 
boiling point, whereas gas-solid chromatography is based on differences of adsorption 
capacity (Neves, 1980). 
In general, a standard chromatography system comprises a source of car rier gas 
and valves for regulating the flow rate, an injector, a column that is put in an oven, a 
detector, and a recorder (Figure 1.3) (Neves, 1980; Skoog et al., 1997). The carrier gas 
should be pure and chemically inert and the most commonly gasses are helium, nitrogen 
and hydrogen. The choice of carrier gas is most often determined by the type of detector 
that is used in combination with the GC (Neves, 1980; Skoog et al., 1997). Helium is the 
most common gas as it is non-flammable and works with a large number of detectors. 
However, worldwide availability of helium has become critical in recent years, resulting in 
increasing prices. Therefore, chromatographers increasingly switch to the use of hydrogen 
gas. 
 
 
Figure 1.3. A general schematic of GC (adapted from Skoog et al., 1997) 
 
Although manual injection of a sample is possible, the use of an autosampler is 
recommended as it provides better reproducibility and is more time-efficient. The injection 
of the sample is an important aspect of the analytical process that can influence the 
efficiency of the chromatography. A slow injection of a large amount of sample induces 
extension of the bands, which results in a bad resolution (Skoog et al., 1997). 
Most injection systems make use of a micro syringe. The sample can be injected 
as gas or as liquid, but in the latter case, the sample is vaporized before it comes onto the 
column. The micro syringe is contained between heated metal blocks that have a suff iciently 
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high temperature to quickly vaporize the sample without decomposing the sample (Neves, 
1980; Skoog et al., 1997). Most injectors allow split and splitless injection mode (Figure 
1.4). Split injection is normally applied for the analysis of compounds in high 
concentrations. The presence of a split line and a split valve, allows that just a part of the 
injected sample enters the column, whereas the remainder is discharged through the split 
line. In this way, it is possible to obtain a chromatogram with very sharp peaks due to the  
rapid sample transfer onto the column (Thermo Scientific, 2014). 
 
 
Figure 1.4. A schematic of the injection system of GC, showing particularly the split line (adapted from Thermo Scientific, 2014) 
 
In splitless mode, the split valve is closed and the entire sample enters the column, 
which is appropriate for compounds with low concentrations (Thermo Scientific, 2014). The 
column, localised inside a specialised oven, is the place where the separation occurs. The 
carrier gas transports the sample from the injector into the column head. Within the column, 
the different components of the mixture are partitioned between the stationary phase and 
the mobile phase allowing the separations of the compounds (Burchfield & Storrs, 1962; 
Neves, 1980; Skoog et al., 1997). 
Nowadays, mainly capillary columns are used which have a small internal diameter 
(0.25 until 0.5 mm) and a length between 12 to 300 m. To fit in the oven, the columns are 
wound in 10 to 30 cm of diameter (Raulin et al., 1999; Skoog et al., 1997). Parameters 
that need to be taken into account when selecting a GC column include the type of stationary 
phase, the internal diameter, the film thickness and the column length. Non-polar stationary 
phases separate components predominantly based on boiling point whereas stationary 
phases that contain phenyl and/or cyanopropyl groups rather separate based on 
differences in molecular dipole moment. Columns with smaller internal diameter allow more 
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efficient separation resulting in a better resolution compared to broader columns. Columns 
with a thick film (requiring also a larger internal diameter) are appropriate for samples with 
large variation in solute concentrations as they prevent overloading of the column. The 
thicker the film, the greater the loading capacity. Increasing the length of the column might 
increase the resolution. However, the shortest column that provides the required resolution 
should be selected. 
The oven temperature needs to be precisely controlled, as the rate at which the 
components pass through the column is directly proportional to the temperature of the 
column. Higher temperatures result in higher rates but also in less interaction with the 
stationary phase of the column and thus less separation. Most methods use a temperature 
program which means that the temperature is gradually increased during the analysis to 
allow adequate separation of highly volatile compounds and acceptable retention times for 
slowly eluting compounds.  
Compounds that elute from the column pass to the detector. The t ime that a 
compound takes to pass from the injector to the detector is entitled the retention time 
(Burchfield & Storrs, 1962; Raulin et al., 1999). 
Most commonly used GC detectors are Thermal Conductivity Detector (TCD), Flame 
Ionization Detector (FID), Electron Capture Detector (ECD) and mass spectrometers (Raulin 
et al., 1999). From those detectors, only the MS provides structural information about the 
analytes. 
The electronic signal produced in the detector is sent to a recorder/ data system 
and is used to construct a plot with the relative abundance (Y -axis) as a function of the 
retention time (X-axis), which is called the chromatogram. The retention time can be useful 
for the identification of the compounds, when compared to a reference library.  
1.3.2. MASS SPECTROMETRY 
Mass Spectrometry (MS) separates compounds according to their mass -to-charge 
(m/z) ratios after ionization (Hill, 1969). A mass spectrometer generally consists of an ion 
source, a mass analyzer, a detector and a recorder/ data system (Davis & Frearson, 1987; 
De Hoffmann, Charette, & Stroobant, 1996). The ion source converts the electrically neutral 
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molecules into ions, by capturing or removing electrons or protons, resulting in a charged 
molecule (Davis & Frearson, 1987; Mikkelsen & Cortón, 2004). There are different ion 
sources that ionize the analytes in different ways. The most common ionization techniques 
are electron impact (EI), chemical ionization (CI), field ionization (FI), field desorption (FD) 
and fast atom bombardment (FAB) (Davis & Frearson, 1987; De Hoffmann et al., 1996). 
Only EI will be discussed here as this is the type of ionization that was used in this project. 
An EI source is composed of an ionization chamber, a heated filament , an anode, and 
lenses (Figure 1.5). Compounds that elute from the GC column, enter the ionization 
chamber of the ion source which is contained under vacuum. The filament is heated by an 
electric current to emit electrons (De Hoffmann et al., 1996). In this way, a current of 
electrons is created in the ionization chamber. When those electrons collide or pass very  
close to the gaseous compounds, an energy transfer can occur, resulting in the expelling of 
an electron from the compounds and the formation of a positive ion. Theoretically, it is also 
possible to produce a negatively charged  ion, the probability of electron capture is about 
100 times less than that of electron removal (Davis & Frearson, 1987; De Hoffmann et al., 
1996). 
 
 
Figure 1.5. A schematic of an ion source of MS (adapted from De Hoffmann et al., 1996) 
 
This type of ionization induces a high degree of fragmentation of the ions that is 
characteristic for the respective compounds and is called hard ionization. Careful analysis 
of the fragmentation patterns and comparison to mass spectral libraries allows st ructural 
elucidation and identification of unknown compounds (De Hoffmann et al., 1996).  A series 
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of lenses positioned outside the ionization chamber extract the  ions from the ionization 
chamber and accelerates them into the mass analyzer (De Hoffmann et al., 1996). 
The mass analyzer separates the ions according their m/z ratios (Davis & Frearson, 
1987; Mikkelsen & Cortón, 2004) and is characterized by the upper mass limit, the 
transmission and the resolution. The upper mass limit is the highest m/z ratio value that 
can be determined. The number of molecules that reached the detector divided by the 
number of ions produced in the source gives the transmission number. The resolution, also 
known as resolving power, indicates the capacity to distinguish signals with a small mass 
difference (De Hoffmann et al., 1996). Different types of mass analyzers are available. In 
this project, a single quadrupole was used and therefore limit the description to this type of 
analyzer. The quadrupole analyzer is composed of four parallel rods (Figure 1.6). The 
diagonal rods are electrically connected, divided into two pairs, creating an electrical field 
(De Hoffmann et al., 1996; Mikkelsen & Cortón, 2004). 
 
 
Figure 1.6. A schematic of a quadrupole analyzer of MS (adapted from De Hoffmann et al., 1996) 
 
A radio frequency (RF) alternating field is created between the 4 rods that selectively 
stabilises or destabilises the paths of the ions passing through the quadrupole. Only the 
ions with a specific m/z ratio (resonant ions) are able to pass through the quadrupole for 
a specific voltage applied on the rods, whereas the other ions have unstable trajectories 
and collide with the rods (non-resonant ions). A quadrupole mass analyzer can be used in 
Singe Ion Monitoring (SIM) modus in which one m/z ion is continuously monitored by 
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keeping the applied voltages constant, or in Full Scan mode (FSM), in which a range of m/z 
values is measured by continuously varying the applied voltages (De Hoffmann et al., 1996; 
Mikkelsen & Cortón, 2004). 
After the mass analyser, the separated ions reach the detector and the number of 
ions with a specific mass is counted. The resulting mass spectrum is a graph that contains 
the number of the ions with different masses that run through the detector (Davis & 
Frearson, 1987; Mikkelsen & Cortón, 2004). 
 
1.4. SAMPLE PREPARATION AND VALIDATION: THEORETICAL POINTS 
1.4.1. SAMPLE PREPARATION 
The BAs that will be analysed in this study are CA, CDCA, DCA, LCA and UDCA 
(structures shown in Figure 1.1). However, those bile acids are not volatile (Table 1.1) and 
therefore, require derivatisation prior to injection into a GC-MS system. 
 
Table 1.1. Boiling Point of BAs (CA, CDCA, DCA, LCA, UDCA) 
 
 
Normally, the derivatisation process turns the sample sufficiently volatile to be 
eluted at reasonable temperatures without thermal decomposition or molecular 
rearrangement. The derivate, in general, is less polar, more volatile and more thermally 
stable (Orata, 2012; Sigma Aldrich, 2011). The derivatisation can also reduce analyte 
adsorption in the GC, this means decrease the adhesion of the analyte to an active surfac e 
of column wall and the solid support, which can improve the symmetry and the shape of 
the peak (Orata, 2012; Sigma Aldrich, 2011). Common derivatisation reactions for GC 
applications are classified into three types: alkylation, acylation and silylation (Sigma 
Aldrich, 2011). 
Alkylation is mostly used as the first step for further derivatisations or as a method 
of protection of certain active hydrogens in a sample molecule (Orata, 2012). The alkylation 
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consists in the replacement of active hydrogen by an alkyl group (Sigma Aldrich, 2011). 
The most popular alkylation reaction is esterification. In this process a carboxylic acid is 
treated with an alcohol and an acid catalyst, to form an ester, releasing a water molecule 
(Figure 1.7). The ester is more volatile than the carboxylic acid (Sigma Aldrich, 2011). 
 
 
Figure 1.7. Representation of a reaction in esterification process, also known as Fischer esterification (adapted from Sigma 
Aldrich, 2011) 
 
The most popular alkylation reaction is esterification. In this process a carboxylic 
acid is treated with an alcohol and an acid catalyst, to form an ester, releasing a water 
molecule (Figure 1.7). The ester is more volatile than the carboxylic acid. Figure 1.8 shows 
the esterification of CA to its butyl ester. 
 
      
Figure 1.8. Representation of reaction in esterification process for Cholic Acid 
 
Derivatisation by acylation converts functional groups with active hydrogen such as 
–OH, -SH, and –NH into esters, thioesters and amides, respectively (Sigma Aldrich, 2011). 
Silylation reactions introduce a silyl group into the analyte, usually in substitution 
for an active hydrogen in the compound. Nearly all functional groups like hydroxyl groups, 
carboxylic acids, thiols, phosphates or amines can be silylated, typically by replacing  a 
proton with a trimethylsilyl group (Orata, 2012). The Figure 1.9 represented the CA and the 
CA butyl ester TMS ether. 
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Figure 1.9. Representation of a – Cholic Acid; b – Cholic Acid after suffer esterification and silylation processes 
    
1.4.2. VALIDATION PROCEDURE 
In 1987 the Food and Drug Administration, from United States, defined validation 
as a “process of establishing through documented evidence a high degree of assurance 
that a specific process will consistently produce a product that meets its predetermined 
specifications and quality attributes” (FDA, 2010). 
The validation procedure of an analytical method involves a number of experiments 
to demonstrate that the method is precise and accurate. In addition, limits of quantitation 
(LOQ) and limits of detection (LOD) were determined (FDA, 2015; Houben, 2010). 
 
 LINEARITY 
To quantify BA concentrations in unknown samples, calibration curves are 
constructed by plotting the peak area ratios of each BA to the internal standard for different 
amounts of BA. The results are fit to a straight line using linear regression analysis. Such 
calibration curves are characterised by a slope, an intercept and a regression coefficient 
(r2). The slope represents the sensitivity of the method whereas the intercept gives an 
indication of the background signal. The value of r 2 represents the adjustment of a 
generalized linear statistical model. The r 2 should be as close as possible to 1. 
Reproducibility of calibration curves is assessed by repeating the experiments on 3 
different days allowing the calculation of the average, standard deviation (STDEV) and 
coefficient of variation (CV) of the three variables. 
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 PRECISION 
The precision of a method is related to its repeatability and indicates the degree to 
which repeated measurements under unchanged conditions show the same results. The 
precision of a method is often indicated by its CV. The CV is the STDEV of the results divided 
by the average of the same results, and multiplied by 100. For a good precision, the CV 
should be low (≤10%). To assess the precision, both the repeatability within one day and 
the repeatability over several days is evaluated.  
  
 INTRADAY VARIABILITY (VARIABILITY IN 1 DAY) 
The variability on the measurements within one day is calculated for standard 
solutions of BA in different concentrations and for real samples.  Three replicates of each 
standard/sample are prepared and analysed on the same day to allow calculating the CV.  
This experiment is repeated on a separate day.  
  
 INTERDAY VARIABILITY (VARIABILITY ON DIFFERENT DAYS) 
The interday variability evaluates the consistency of the results on different days. 
Therefore, standard BA solutions and samples were analysed on 3 dif ferent days to allow 
calculating the CV on these averages.  
  
 ACCURACY 
Accuracy indicate the closeness between the measured value and the true value 
(Figure 1.10). 
 
Figure 1.10. Schematic representation of accuracy and precision (Pekaje, 2007) 
For standard solutions, it is the deviation of the measured value from the true value 
on the calibration curve, expressed as relative error. 
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For unknown samples, accuracy of the measurements is estimated from recovery 
experiments. This implicates that the concentration of each BA is measured in the sample 
as such (before spike) after which the sample is spiked with a known concentrations  of the 
component and measured again (after spike). The difference in concentration between the 
sample after and before spike divided by the added concentration in the spike and multiplied 
by 100 is the recovery of the sample and should be between 80 and 120%. 
  
 LIMIT OF QUANTIFICATION 
The limit of quantification (LOQ) reveals the lowest concentration of an analyte that 
can be reliably quantified. The LOQ can be defined as the concentration at which the 
CV≤15% (Armbruster & Pry, 2008). 
Alternatively, to the LOQ is defined as the concentration that corresponds  to 
10-20 times the noise level (Figure 1.11) (Huber, 2007). 
 
 LIMIT OF DETECTION 
The limit of detection (LOD) indicates the lowest concentration of an analyte that 
can be detected (Armbruster & Pry, 2008; Shrivastava, 2011). It is defined as the 
concentration that corresponds to a signal that is 2-3 times the height of the noise level, 
Figure 1.11 (Huber, 2007; Shrivastava, 2011; Skoog et al., 1997). 
 
 
Figure 1.11. A schematic representation of LOD and LOQ basing on the noise level 
  
 
 
 
 
 
 
 
 
 
CHAPTER 2 
MOTIVATION AND OBJECTIVES
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2.1. MOTIVATION 
  
About 5% of bile acids (BAs) escape to enterohepatic recirculation. This escape 
means that the BAs are not reabsorbed in the terminal ileum going directly to the large 
bowel, where they are metabolized and end up excreted in faeces. 
The BAs, as mentioned previously, have been implicated in a number of diseases 
such as obesity, type 2 diabetes, hyperlipidemia, cirrhosis, inflammatory bowel disease 
(IBD) and inflammatory bowel syndrome (IBS). Another diseases like large bowel cancer, 
colon and colorectal cancer are also related with BAs. For these extensive association with 
disorders and diseases, it is important analyse faecal BAs in order to use them as a 
biochemical markers. Theses markers might be in further a promising way to diagnosis the 
development of these disorders and hopefully prevent them. 
There are already some studies that used HPLC, GC-MS and LC-MS to analyse 
faecal BAs, (Batta et al., 1999; Courillon, Gerhardt, Myara, Rocchiccioli, & Trivin, 1997; 
Genta Kakiyama et al., 2014), however none of these methods are validate. The validation 
process allows the reproducibility of the method, this means that if the same conditions of 
one method are made, the results obtained have to be the same, for equivalent samples.  
 
2.2. OBJECTIVES 
 
The main purpose of this dissertation is to develop and validate an analytical 
procedure for the analysis of faecal bile acids using GC-MS. 
The first priority of this work was to obtain valid chromatograms, with correct shape 
peaks, which appear well separate and with good internal standard. After this goal achieved, 
the further steps were the optimization of all the procedures that occur before the GC 
injection. 
As bile acids are not volatile as such, a derivatisation step was included in the 
sample preparation protocol. The derivatisation processes, esterification and silylation, 
were optimised by varying conditions like the amount of reagent, reaction time and 
temperature. 
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After obtaining a developed method, the precision and accuracy of calibration points 
have to be inside of the defined parameters, and posteriorly the precision and accuracy of 
faecal samples also have to correspond to the parameters established to consider this 
method valid.
  
 
 
 
 
 
 
 
 
 
CHAPTER 3 
MATERIALS AND METHODS
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3.1. CHEMICAL REAGENTS AND SOLUTIONS 
 
CA 97%, CDCA ≥97%, DCA 98.5%, UDCA 99% and LCA 98% were purchased from 
Sigma Aldrich (Germany). HDCA 98% (TCI Chemicals, Tokyo) was used as internal standard. 
Hydrochloric acid 37% fuming (HCl) and ethanol absolute were obtained from Merck 
KGaA (Germain) and butanol-(1) 99.5% was purchased from Chem-Lab NV (Belgium). 
Hexane Chromasolv for HPLC ≥97% (GC) was obtained from Sigma-Aldrich (Germany). 
Sodium Hydroxide (NaOH) was purchased from VWR Chemicals (Belgium) and the 
Supplier was Aldon Corporation SE. 
The mixtures used for derivatisation HMDS+TMCS+Pyridine (Hexamethyldisilazane, 
Trimethylchlorosilane, Pyridine (3:1:9)) and N,O-bis(trimethylsilyl)acetamide, 
Trimethylchlorosilane, N-trimethylsilyimidazole (BSA+TMCS+TMSI; 3:2:3) were purchased 
from Sigma Aldrich (Germany) whereas N,O-bis(trimethylsilyl)trifluoroacetamide with  1% 
Trimethylchlorosilane (BSTFA+TMCS) was obtained from Grace Davison Discovery Science. 
 
3.2. SAMPLE PREPARATION 
3.2.1. PREPARATION OF STOCK SOLUTIONS AND FAECAL SAMPLES 
Standard stock solutions were prepared by dissolving each BA in butanol with a 
concentration of 10 µg/µl for each compound. These standard stock solutions were further 
diluted 1:10 with butanol to obtain a concentration of 1 µg/µl.  
A mixed standard solution was made containing the 5 bile acids, CA, CDCA, DCA, 
DCA, UDCA and LCA. The concentration of each compound in this solution was 0.1 µg/µl. 
For the reflux experiment, solutions of the BA with the same concentrations were prepared 
in ethanol. These mixed solutions were further diluted with butanol or ethanol, respectively, 
to obtain different concentrations of standard solutions to prepare calibration curves. 
To validate the method, faecal samples collected at the University Hospital UZ 
Leuven were either freeze-dried during 70 h (Alpha 1-4 LSC, Christ) (freeze dried stool), or 
centrifuged at 50000 × G at 4°C for 2 h (Optima LE-80K Ultracentrifuge, Beckman) to 
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prepare faecal water (FW) that was further dried under a N 2 atmosphere.  
3.2.2. SAMPLE PREPARATION 
To each sample, or standard solution (0.1 µg/µl), 100 µl of internal standard 
[0.1 µg/µl] was added and each sample was then diluted with butanol up to a total 
volume of 200 µl. 
The samples were sonicated for 5 min to 90 min (Ultrasonic Cleaner, VWR, 
Leuven, Belgium). 
3.2.3. ESTERIFICATION 
The endstanding carboxyl function of the BAs was converted to an ester using 
butanol as an alcohol in the presence of an acid catalyst (50 µl HCl 12N or 20 µl H 2SO4 
36N). The amount of butanol ranged between 50 µl and 200 µl. After adding the acid 
catalyst, all samples were vortexed for 5 s, to homogenise the mixture. The solutions were 
subsequently incubated at 60°C or 70°C for 30 min to 4 h. After cooling, the samples were 
centrifuged at 1500 × G at room temperature for 5 min. These samples were dried with a 
N2 stream until complete dryness. 
3.2.4. SILYLATION 
Silylation of the hydroxyl groups of the BAs was performed by addition of 25-100 µl 
of a silylation mixture (HMDS+TMCS+Pyridine (3:1:9), BSTFA+TMCS or BSA+TMCS+TMSI) 
to the dry residue. The samples were heated at 55°C, 60°C or 70°C for 30 min to 24 h. 
After centrifugation of the samples for 5 min, at 1500 × G at room temperature, samples 
were dried with a N2 stream until complete dryness. 
3.2.5. EXTRACTION 
The derivatised BAs were extracted using 200 µl of hexane. After centrifugation of 
the organic layer, the samples were analysed on a GC-MS.  
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3.2.6. REFLUX 
To increase the solubilisation of the BAs in faecal samples, faecal samples were 
suspended in 5mL of absolute ethanol to which 400µl of NaOH 0.15M was added. After 
sonication, the solutions were refluxed in a block heater for 1 h at 80 °C. After 
centrifugation 10 min at 1500 × g, the supernatant was transferred to new vials and dried 
at 80°C for 40 min. Subsequently, samples were esterified, silylated and extracted as 
described above. 
The recovery tests were performed by analysing the faecal samples as such and 
after spiking with different amounts of mixed standard solution (0.2 µg and 10 µg of BA). 
3.2.7. GC-MS ANALYSIS 
The gas chromatograph used was a Trace 1300 from Thermo Scientific and the 
mass spectrometer used was a DSQ II from Thermo Scientific. 
During this project, two GC-columns were used. The first column was a HP-5MS, 
(5%-Phenyl)-methylpolysiloxane with 30 m of length, 0.25 mmID, 0.25 µm df, from 
Agilent J&W. The second column was an Rxi-1ms, Crossbond® 100% dimethyl polysiloxane 
with 30 m of length, 0.25 mmID, 0.25 µm df, from Restek. 
The autosampler was a robotic GC pal system from Interscience. 
Helium (>99.9996%) was used as a carrier gas with a constant flow of 1.0 ml/min 
or 1.5 ml/min. Mass spectrometric detection was performed either in full scan mode from 
m/z 59 to m/z 590 at 2 scans/s or in single-ion-mass mode for masses m/z 215.00, 
m/z 253.00 and m/z 255.00. 
 
3.3. LINEARITY AND DETECTION LIMITS 
 
To evaluate the linearity, calibration curves were made with different concentrations 
of mixed standard solution (solution with 5 bile acids, CA, CDCA, DCA, UDCA and LCA). 
Amounts of BAs varied from 0.05 µg to 50 µg.  
Recovery tests were performed by analysing the faecal samples as such and after 
spiking with different amounts of mixed standard solution (1 µg and 10 µg of BA). 
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CHAPTER 4 
RESULTS AND DISCUSSION 
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4.1. INSTRUMENT METHOD DEVELOPMENT 
 
Standard solutions of bile acids (20 µg of each BA) were esterified with butanol by 
addition of 50 µl HCl 12N and incubation for 4 h at 60°C and subsequently silylated with 
100 µl of HMDS+TMCS+Pyridine (3:1:9) and incubation for 30 min at 55°C. 
The GC-MS method described by (Keller & Jahreis, 2004) was used as the starting 
point. The GC-column was a HP-5MS column (Courillon, Gerhardt, Myara, Rocchiccioli, & 
Trivin, 1997) and the temperature program ranged from 150°C to 298°C as depicted in Figure 
4.1. For this first method, the helium flow was set at 1.0 ml/min and samples were injected 
in a splitless mode. The MS was operated in full scan. 
 
 
Figure 4.1. Temperature program data of first method 
 
The chromatograms, obtained under the conditions described for method 1, of CA, 
HDCA (internal standard) and of a mixture solution are presented in Figure 4.2. 
 
Figure 4.2. GC chromatograms resultants of initial experiments analysis in a range of retention time since 37.97 until 47.52 for a – 
CA; b – HDCA; c – mixture (LCA, DCA, CDCA, CA and UDCA) 
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It is clear from those chromatograms that the shape of the peaks was not symmetric 
with fronting in all BA peaks. In addition, the peaks had a rather long retention time with the 
first peak of interest only eluting from the column after more than 39 min. Furthermore, CA 
and CDCA were not separated and coeluted from the column when analysing the mixture of 
BAs. 
Therefore, the temperature program was modified for this second method by 
accelerating the increase in temperature, to reduce the retention time, as shown in Figure 4.3, 
In addition, the helium flow was increased from 1.0 ml/min to 1.5 ml/min. 
 
 
Figure 4.3. Temperature program data of second method 
 
Figure 4.4 shows the combination of the individual chromatogram in just one 
chromatogram, obtained with the second method settings. 
 
 
Figure 4.4. GC chromatogram obtained due combination of individual chromatograms (CA, CDCA, DCA, LCA and UDCA) and HDCA 
chromatogram analysed in a range of retention time from 18.00 to 32.00 
 
These modifications on the temperature program resulted in a clearly more symmetric 
peak shape and shorter retention times. Under these conditions, LCA elutes already after 
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20 min from the column.  
Unfortunately, although separation between CDCA and CA was improved, the 
separation between both compounds was still far from a baseline separation.  
A further possibility to get smaller peaks and improve separation is to change the 
injection modus from splitless to split.  
However, applying a split flow of 50 ml/min or 25 ml/min did not further improve nor 
deteriorate the separation between CA and CDCA. To prevent overloading of the column and 
contamination of the ion source, the use of split injection with a split flow of 25 ml/min was 
kept in all further experiments. 
 
4.1.1. COLUMN HP-5MS VERSUS COLUMN RXI-1MS 
 
Since the CA and CDCA peaks were overlapping, the analytical column was switched 
from a HP-5MS column (Courillon et al., 1997), which contained 95% of polysiloxane, to a 
more apolar Rxi-1MS column containing 100% polysiloxane (Batta et al., 1999). Figure 4.5 
shows the chromatograms obtained with the HP-5MS and the Rxi-1MS columns. 
 
 
Figure 4.5. Analysis of a BA mixture on a HP 5MA column – a; Rxi 1MS column – b; using second method 
 
It is clear that the Rxi-1MS analytical column solved the problem of overlapping CA and 
CDCA peaks. 
Using this column, all peaks were separated and could be identified and quantified. As 
there was no further need to measure in full scan mode, all further experiments were 
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performed in single ion monitoring mode. Reducing the number of ions to be measured results 
in improved sensitivity. 
 
4.2. OPTIMIZATION OF THE DERIVATISATION PROCEDURE 
4.2.1. STANDARD SOLUTIONS 
4.2.1.1. CONDITIONS OF ESTERIFICATION 
Three aspects were taken into consideration during the esterification: the temperature 
the time and the type of acid catalyst. 
 TEMPERATURE AND TIME 
The impact of the temperature and time during the esterification reaction is shown in  
Figure 4.6. It was possible to observe that extending the time up to 24 h did not improve the 
esterification and even resulted in lower peak areas for CDCA and CA.  
Since the results are difficult to analyse just with Figure 4.6, a statistical analysis was 
made. The two parameters, temperature and time, were evaluated separately with F -test in the 
one-way anova. 
For temperature, after analyzing Table 4.1 and Figure 4.7 it is possible to conclude 
that independently of BAs, there are no statistically significant differences between any pair of 
means at the 95.0% confidence level. Therefore, and taking into consideration the savings 
energy, the lowest temperature, i.e. 60°C, was selected to be used in all further experiments.  
According with Table 4.2 and Figure 4.8, for time, it is possible to see that there are 
statistically significant differences with three groups: - 2 h and 4 h; 0.5, 1, 1.5, 6 and 16 h; and 
24 h. Since the intensity of the area is bigger for 2 and 4 h hours category, the optimized time 
chosen was the lowest value 2 h. 
To conclude, for esterification the optimized temperature was 60°C and the optimized 
time was 2 h. 
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Figure 4.6. Peak areas, obtained by GC-MS, of the individual BAs as a function of time (30 min-24h) and temperature (60°C or 70°C) 
during esterification. The blue points represent the experiment at 60°C and the orange ones represent at 70°C 
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 ACID CATALYST 
The esterification of acids with alcohols requires a strong (non-carboxylic) acid as 
catalyst. As in many cases (Batta et al., 1999; Birk, Dippold, Wiesenberg, & Glaser, 2012; 
Courillon et al., 1997; Keller & Jahreis, 2004) the HCl 12N was tested, in parallel with H 2SO4 
36N. 
The results (Figure 4.9) demonstrate that H2SO4 as a acid catalyst clearly decreased 
the efficiency of the esterification reaction. Only a small peak of LCA could be observed in the 
chromatogram whereas the remaining BAs were not esterified. No further experiments were 
performed using H2SO4, and HCl was used in all further experiments. 
 
 
Figure 4.7. Box and Whisker Plot of different temperatures in esterification, 
for a confidence level of 95.0% 
Figure 4.8. Box and Whisker Plot of different times in esterification, for a 
confidence level of 95.0% 
Table 4.1. F-test table that indicated the statistically significant difference 
to different temperatures in esterification, for a confidence level of 95.0% 
Table 4.2. F-test table that indicated the statistically significant difference 
to different times in esterification, for a confidence level of 95.0% 
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Figure 4.9. GC chromatograms of a mixture standards solution of BAs using a – HCl; b – H2SO4  for esterification 
 
 
4.2.1.2. CONDITIONS OF SILYLATION 
A few parameters are important to optimise the conditions of silylation. Four of them 
have been tested, which are the type and amount of silylation reagent, the temperature, and 
the time of silylation.  
 SILYLATION REAGENT 
i. HMDS+TMCS+Pyridine (3:1:9) versus BSTFA+1%TMCS 
The HMDS+TMCS+Pyridine (3:1:9) solution had been described in previous studies to 
silylate BA (Batta et al., 1999; Keller & Jahreis, 2004). The efficiency of HMDS+TMCS+Pyridine 
(3:1:9) and BSTFA+1%TMCS was compared to silylate a mixed standard solution of BAs. The 
resulting chromatograms are presented in Figure 4.10. 
 
 
Figure 4.10. GC chromatograms of a mixed standard solution of BAs obtained with a – BSTFA+1%TMCS; b – HMDS+TMCS+Pyridine 
(3:1:9) as silylating reagent 
 
When BSTFA+1%TMCS was used as silylating reagent, the DCA peak was clearly 
smaller than when using HMDS+TMCS+Pyridine (3:1:9). No peak at the retention time of CDCA 
nor CA was observed whereas additional peaks eluted in the last part of the chromatogram.  
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Figure 4.11 shows the chromatograms of the individual BAs after derivatisation with 
BSTFA+1%TMCS. 
 
 
Figure 4.11. GC chromatograms of standard solutions of BAs (a – UDCA; b – LCA; c – DCA; d – CDCA; e – CA; f – mixed standard 
solution) obtained with BSTFA+1%TMCS as silylating reagent 
 
It is likely that BSTFA+1%TMCS is a less strong silylating reagent compared to 
HMDS+TMCS+Pyridine (3:1:9), resulting in silylation of only one or two hydroxyl groups. Those 
mono- or di-silylated derivatives of the BAs are more polar and less volatile than the tri -silylated 
analogue and therefore have a longer retention time on the GC-column (Drozd, 1981; Kataoka, 
1996). Increasing the temperature to 70°C and extending the duration of incubation to 24 h 
did not improve the efficiency of the silylation reaction as is shown in Figure 4.12. 
As already mentioned, with these results, even raising the temperature and the time, 
it is possible to conclude that BSTFA+1%TMCS solution is not capable, not strong enough, to 
silylate all the hydroxyl groups. For this reason, the HMDS+TMCS+Pyridine (3:1:9) was used 
in further experiments. 
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Figure 4.12. GC chromatograms of a mixed standard solutions of BAs using BSTFA+1%TMCS as silylating reagent at 70°C for a – 0.5 
h; b – 1 h; c – 1.5 h; d – 2 h; e – 4 h; f – 6 h; g – 8 h; h – 24 h 
 
ii. HMDS+TMCS+Pyridine (3:1:9) versus BSA+TMCS+TMSI (3:2:3) 
According to Suzuki et al., (1997), the addition of TMSI, to the mixture of BSA+TMCS 
might increase the silylating capacity for even strongly hindered hydroxyl groups. Figure 4.13 
shows the chromatograms of the mixed standard solution of BAs and the individual solutions  
using BSA+TMCS+TMSI as silylating reagent. 
After observing the results (Figure 4.13), it was possible to confirm that the addition of 
TMSI to the silylating reagent improved the derivation of CA and CDCA, but resu lted in multiple 
peaks for UDCA. Therefore, the original reagent HMDS+TMCS+Pyridine (3:1:9) was kept in all 
further experiments. 
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Figure 4.13. GC chromatograms with BSA+TMCS+TMSI for a – mixture; b – UDCA; c – LCA; d – DCA; e – CDCA; f – CA 
 
 AMOUNT OF SILYLATION REAGENT 
The amounts of silylation reagent were varied from 25 µl to 100 µl. The areas of each 
BA increased with increasing amount of silylating reagent (Figure 4.14). 
 
 
Figure 4.14. Impact of different amounts of HMDS:TMCS:Pyridine on the peak areas of the resulting BA derivatives 
 
After analysing all the results, it is possible to conclude that 100 µl is the amount more 
favourable when compared with 25 µl and 50 µl. Therefore, all further experiments were 
performed with 100 µl of silylating reagent. 
 TEMPERATURE AND TIME 
The temperature of the silylation reaction was varied between 55°C and 70°C. For each 
incubation temperature, time of incubation ranged from 30 min, to 8 h (Figure 4.15). 
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Figure 4.15. Peak areas, obtained by GC-MS, of the individual BAs as a function of time (30 min-8h) and temperature (50°C, 60°C or 70°C) during silylation. The green symbols represent the 55°C, the purple 
symbols show the results for 60°C and the orange symbols symbolize the 70°C 
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As the results are not consistently for all BAs, it was made a statistical analysis. The 
Table 4.3 and Figure 4.16 represent the statistical analysis results for temperature and Table 
4.4 and Figure 4.17 represent the same results for time. It is possible to see that, 
independently of BAs, for both parameters there are no statistically significant differences 
between any pair of means at the 95.0% confidence level. For this reason, it was decided to 
choose the lowest temperature for economic reasons (saving energy) and the lowest time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To conclude, for silylation the optimized temperature was 55°C and the optimized time 
was 30 min. 
 
4.2.2. FAECAL SAMPLES: ADDITION OF A SONICATION STEP 
Lyophilised faecal samples were suspended in butanol and subjected to sonication 
prior to esterification in an attempt to increase the efficiency of the derivatisation procedure. 
Table 4.3. F-test table that indicated the statistically significant difference 
to different temperatures in silylation, for a confidence level of 95.0% 
Table 4.4. F-test table that indicated the statistically significant difference 
to different times in silylation, for a confidence level of 95.0% 
Figure 4.16. Box and Whisker Plot of different temperatures in silylation, for a 
confidence level of 95.0% 
Figure 4.17. Box and Whisker Plot of different times in silylation, for a 
confidence level of 95.0% 
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Figure 4.18 shows the impact of duration of this sonication step. 
 
 
Figure 4.18. Results of areas obtained in different times of sonication in CA, CDCA, DCA, LCA and HDCA. The CA and CDCA have the 
values of right scale 
 
Increasing the time of sonication increased the area of the resulting BA derivatives. A 
maximal increase was observed after 90 min of sonication. Therefore, this sonication for 
90 min was included in the preparation of all samples and standard solutions for the validation 
process. 
 
4.3. VALIDATION PROCEDURE 
4.3.1. STANDARD SOLUTIONS 
 PRECISION (INTRADAY AND INTERDAY VARIABILITY) 
The precision of the measurement of the solutions was evaluated by analysing each 
dilution three times on the same day (intraday variability). For each BA and each amount of 
BA, the CV was calculated (Table 4.5). This analysis was repeated on three consecutive days. 
The mean value for each BA per day was used to calculate the CV over three days reflecting 
the interday variability (Table 4 6). 
For the solutions with amounts of BAs up to 0.5 µg, the intraday variability exceeded 
the accepted limit of 10% on at least 1 day. Nevertheless, the interday variability remained 
below 10% for all BAs and all amounts except for 0.05 µg. 
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Table 4.5. Intraday variability (n=3) on measurement of individual bile acids, expressed as CV. The measurements that fulfil the criterion (CV≤10%) are coloured in green 
 
 
 
 
 
 
 
 
 
 CV of three measurements performed on the same day 
Amount of BA 
 
CA CDCA DCA LCA UDCA 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
0.05 70 14 1 56 26 6 81 21 4 90 12 6 67 14 22 
0.1 15 10 13 11 7 10 8 8 17 6 3 19 22 12 6 
0.25 19 5 1 12 5 1 15 6 8 9 6 5 14 6 3 
0.5 12 1 5 14 3 4 11 1 3 7 6 3 9 3 3 
0.75 9 2 5 10 1 5 10 2 5 3 1 5 13 3 4 
1 6 6 3 6 5 4 5 5 7 4 3 5 5 3 2 
2.5 3 7 11 3 7 11 2 9 10 4 11 8 2 8 9 
5 7 4 1 8 5 1 4 5 0 8 6 1 4 4 0 
7.5 5 2 2 7 3 6 9 2 1 8 5 6 5 3 2 
10 8 4 4 5 5 5 3 5 2 2 8 1 2 4 1 
25 11 5 8 13 9 9 6 5 11 3 8 12 8 4 9 
50 7 5 3 8 6 3 5 7 4 7 9 6 4 6 5 
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Table 4 6. Interday variability (n=3) on measurement of individual bile acids, expressed as CV. The measurements that fulfil the criterion (CV≤10%) are coloured in green and the measurement that do not fulfil the 
criterion are coloured in red 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
BA Parameters 
Amount of BA (µg) 
0.05 0.1 0.25 0.5 0.75 1 2.5 5 7.5 10 25 50 
CA 
Average 0.078 0.109 0.253 0.519 0.819 1.157 2.452 4.975 7.794 11.954 30.762 54.201 
STDEV 0.013 0.003 0.014 0.011 0.021 0.019 0.027 0.076 0.087 0.048 1.516 4.369 
CV 16 3 6 2 3 2 1 2 1 0 5 8 
CDCA 
Average 0.073 0.104 0.251 0.517 0.796 1.100 2.341 5.063 7.874 11.134 27.524 53.616 
STDEV 0.011 0.001 0.019 0.011 0.023 0.020 0.029 0.056 0.164 0.119 0.854 0.345 
CV 15 1 7 2 3 2 1 1 2 1 3 1 
DCA 
Average 0.077 0.108 0.271 0.544 0.845 1.331 2.512 5.209 8.271 11.860 28.340 56.998 
STDEV 0.020 0.007 0.018 0.015 0.020 0.024 0.015 0.021 0.171 0.117 1.034 0.424 
CV 27 7 7 3 2 2 1 0 2 1 4 1 
LCA 
Average 0.082 0.107 0.265 0.543 0.854 1.164 2.518 5.195 8.286 11.947 28.666 57.162 
STDEV 0.023 0.008 0.019 0.015 0.024 0.017 0.013 0.051 0.142 0.098 0.462 0.194 
CV 28 8 7 3 3 1 1 1 2 1 2 0 
UDCA 
Average 0.071 0.107 0.256 0.511 0.797 1.129 2.424 5.011 7.947 11.366 29.206 53.794 
STDEV 0.008 0.005 0.005 0.019 0.010 0.014 0.021 0.071 0.195 0.145 0.918 0.374 
CV 12 5 2 4 1 1 1 1 2 1 3 1 
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 LIMITATION OF QUANTIFICATION AND DETECTION 
The limit of quantification (LOQ) is the lowest amount of compound with a CV below 15%. 
The interday CV fulfilled this criterion for all BAs at an amount of 0.1 µg and was even 0.05 µg for 
UDCA (Table 4 6). 
The limit of detection (LOD) was determined based on the signal-to-noise ratio (SN). 
The LOD is defined as the concentration that corresponds 2-3 times to the height of the noise 
level. Figure 4.19 shows a chromatogram of a solution containing 0.05 µg of each BA.  
 
Figure 4.19. GC chromatogram of standard solution containing 0.05 µg of each BA 
 LINEARITY 
The measurements presented in Table 4.7 were used to construct three different 
calibration curves in different concentration ranges, each characterized by a slope, intercept 
and regression coefficient (r2). These curves were prepared on 3 different days. The results 
can be found in Table 4.7. 
The minimal value of the regression coefficient, r 2, was 0.9788 and the majority of the 
values were higher than 0.99 indicating a good linearity of the calibration curves.  
 
  
LCA DCA UDCA 
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Table 4.7. Characteristics of calibration curves for each BA constructed on 3 different days 
 
 
 INTRADAY 
The CV on the slope, intercept and regression coefficient values on the 3 days was 
calculated as a measure of the interday variability (Table 4.8).  
The CV of slope and r2 values was consistently lower than 10%. However, the variability 
of the intercept was higher for all BAs in the low-range calibration curve and for all BAs but CA 
in the high range calibration curve. 
 
  
BAs 
Stock 
Solutions 
(µg) 
Day 1   Day 2 Day 3 
slope intercept r² slope intercept r² slope intercept r² 
LCA 
0.05 – 1 0.0935 0.0017 0.9955 0.0963 -0.0005 0.9963 0.0940 -0.0001 0.9980 
0.5 – 10 0.1652 -0.1093 0.9889 0.1737 -0.1123 0.9883 0.1634 -0.1056 0.9919 
5 – 50 0.2835 -0.9602 0.9995 0.2341 -0.4151 0.9998 0.2658 -0.7827 0.9994 
DCA 
0.05 – 1 0.1434 0.0034 0.9972 0.1451 -0.0001 0.9959 0.1442 0.0007 0.9988 
0.5 – 10 0.2578 -0.1593 0.9914 0.2669 -0.1739 0.9881 0.2552 -0.1568 0.9928 
5 – 50 0.4382 -1.4523 0.9995 0.4155 -1.2083 0.9989 0.3943 -0.9643 0.9986 
CDCA 
0.05 – 1 0.0357 -0.0001 0.9970 0.0354 -0.0004 0.9952 0.0348 -0.0002 0.9991 
0.5 – 10 0.0584 -0.0221 0.9940 0.0603 -0.0262 0.9913 0.0581 -0.0230 0.9950 
5 – 50 0.0829 -0.1660 0.9999 0.0819 -0.1203 0.9998 0.0764 -0.0797 0.9974 
CA 
0.05 – 1 0.0984 -0.0009 0.9945 0.0975 -0.0023 0.9913 0.0941 -0.0016 0.9971 
0.5 – 10 0.2183 -0.1716 0.9827 0.2198 -0.1783 0.9788 0.2226 -0.1914 0.9801 
5 – 50 0.2429 -0.3819 0.9864 0.2468 -0.4091 0.9825 0.2512 -0.4364 0.9870 
UDCA 
0.05 – 1 0.0404 -0.0005 0.9978 0.0400 -0.0012 0.9923 0.0388 -0.0009 0.9967 
0.5 – 10 0.0736 -0.0417 0.9941 0.0763 -0.0497 0.9871 0.0726 -0.0449 0.9922 
5 – 50 0.0946 -0.0851 0.9981 0.0895 -0.0287 0.9983 0.0855 -0.0058 0.9919 
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Table 4.8. CV of the slope, intercept and r2 value of calibration curves constructed on 3 days. The measurements that fulfil the 
criterion (CV≤10%) are coloured in green and the measurement that do not fulfil the criterion are coloured in red 
 
 
 
  
 ACCURACY 
Table 4.9 shows the accuracy of the calibration points which is expressed as the 
relative error between the measured value and the true value. The results are the mean values 
for the measurements on 3 days and triplicate samples. Only the lowest amount of BAs 
(0.05 µg) display a relative error above 10% whereas the accuracy is within the limits of 10% 
deviation for all other amounts of BA. 
Stock 
Solution 
(µg) 
  CA CDCA DCA LCA UDCA 
0.
05
 –
 1
 
slope 
Average 0.0967 0.0353 0.1442 0.0946 0.0397 
STDEV 0.0023 0.0004 0.0009 0.0015 0.0008 
CV 2.33 1.27 0.59 1.58 2.04 
intercept 
Average -0.0016 -0.0002 0.0013 0.0004 -0.0008 
STDEV 0.0007 0.0002 0.0018 0.0012 0.0004 
CV -41.91 -86.39 139.42 328.84 -42.58 
r2 
Average 0.9943 0.9971 0.9973 0.9966 0.9956 
STDEV 0.0029 0.0020 0.0014 0.0013 0.0029 
CV 0.29 0.20 0.14 0.13 0.29 
0.
5 
– 
10
 
slope 
Average 0.2202 0.0589 0.2600 0.1674 0.0742 
STDEV 0.0022 0.0012 0.0061 0.0055 0.0019 
CV 0.99 2.05 2.36 3.28 2.53 
intercept 
Average -0.1805 -0.0238 -0.1633 -0.1091 -0.0454 
STDEV 0.0101 0.0021 0.0093 0.0034 0.0040 
CV -5.57 -9.02 -5.68 -3.09 -8.83 
r2 
Average 0.9805 0.9935 0.9908 0.9897 0.9911 
STDEV 0.0020 0.0019 0.0024 0.0020 0.0036 
CV 0.20 0.19 0.24 0.20 0.36 
5 
– 
50
 
slope 
Average 0.2470 0.0804 0.4160 0.2611 0.0898 
STDEV 0.0042 0.0035 0.0219 0.0250 0.0046 
CV 1.69 4.37 5.27 9.59 5.10 
intercept 
Average -0.4091 -0.1220 -1.2083 -0.7193 -0.0399 
STDEV 0.0273 0.0432 0.2440 0.2780 0.0408 
CV -6.66 -35.39 -20.19 -38.65 -102.30 
r2 
Average 0.9853 0.9990 0.9990 0.9996 0.9961 
STDEV 0.0024 0.0014 0.0005 0.0002 0.0036 
CV 0.25 0.14 0.05 0.02 0.36 
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Table 4.9. Mean relative error of each calibration point and each BA. The measurements that fulfil the criterion (CV≤10%) are coloured 
in green and the measurement that do not fulfil the criterion are coloured in red 
 
Concentration 
points 
BAs 
LCA DCA CDCA CA UDCA 
0.05 -44 -34 -36 -40 -29 
0.1 6 5 4 2 1 
0.25 7 5 7 9 6 
0.5 5 4 4 7 6 
0.75 0 1 1 2 3 
1 -2 -2 -2 -4 -3 
2.5 8 8 10 10 10 
5 8 6 3 10 8 
7.5 3 3 2 7 3 
10 5 -4 -3 -7 -4 
25 0 0 -2 -10 -7 
50 0 0 0 3 1 
 
4.3.2 FAECAL SAMPLES 
 PRECISION 
Three different freeze-dried stool samples (S1, S2, S3) and three faecal water samples 
(FW1, FW2, FW3) that were dried under N 2 were used for the validation of the method. The 
samples were analysed as such and again after spiking with 1 µg of each BA (spike 1) and 
with 10 µg of each BA (spike 10). The average and SD (Annex A - Average and Standard 
Deviation values for faecal samples), and the CV (Table 4.10) reflect the intraday precision. 
It is clear that the precision of both stool samples and faecal water is inferior to that of 
the standard solutions as only 38 out of the 80 BAs measurements displayed a CV below 10%.  
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Table 4.10. Intraday variability (n=3) on measurement of individual bile acids, expressed as CV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ACCURACY 
The accuracy of the BAs measurement in faecal samples was calculated from the 
recovery of the spiked samples and is shown in Table 4.11. 
 
Table 4.11. Recovery of spiked (0.2 µg and 10 µg) stool samples and faecal water samples 
 
 
 
 
 
 
 
 
Samples CA CDCA DCA LCA UDCA 
S1  9 38 11 3 16 
S1 spike 1 24 11 15 3 3 
S1 spike 10 112 130 76 5 24 
S2  39 39 23 5 10 
S2 spike 1 9 8 4 5 5 
S2 spike 10 11 12 15 3 2 
S3  1 9 20 17 11 
S3 spike 1 16 23 9 6 5 
S3 spike 10 85 85 74 12 5 
FW1 28 14 13 13 1 
FW1 spike 1 62 46 36 25 3 
FW1 spike 10 58 40 46 17 7 
FW2 10 16 23 19 31 
FW2 spike 1 8 13 4 4 4 
FW2 spike 10 1 3 1 1 1 
FW3 139 135 93 15 5 
FW3 spike 1 55 53 38 5 13 
FW3 spike 10 42 38 29 3 5 
Samples CA CDCA DCA LCA UDCA 
S1 spike 1 109.67 92.00 66.27 1.014.28 163.12 
S1 spike 10 47.19 81.04 0.85 125.65 103.17 
S2 spike 1 2.453.42 1.241.18 665.82 267.66 225.92 
S2 spike 10 170.86 137.71 144.59 150.71 122.65 
S3 spike 1 1.767.36 1.187.45 197.15 259.89 435.64 
S3 spike 10 717.27 510.72 91.48 137.89 119.01 
FW1 spike 1 9.66 1.02 28.43 430.65 192.72 
FW1 spike 10 4.48 8.14 27.70 185.02 121.89 
FW2 spike 1 766.18 299.48 200.55 231.68 162.99 
FW2 spike 10 170.20 143.28 148.35 142.08 115.85 
FW3 spike 1 174.72 176.92 212.36 276.65 169.97 
FW3 spike 10 30.66 5.95 77.89 156.26 124.70 
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In the majority of the cases, recovery values were out of the acceptable range (between 
80 and 120%) which is most likely due to the imprecision of the measurements.  
 REFLUX 
The high imprecision of the faecal samples compared to the standard solutions might 
be attributable to matrix effects and unreproducible derivatisation and extraction of the BAs. 
Therefore, it was investigated whether solubilisation of the BAs in ethanol by refluxing the dried 
faecal (water) samples prior to sonication and derivatisation, could improve the precision and 
accuracy of the BA quantification. A freeze dried stool sample was analysed as such and after 
spiking with 0.2 µg and 10 µg of each BA. Table 4.12 shows the intraday precision of the 
samples whereas the accuracy is shown in Table 4.13.  
 
Table 4.12. Intraday precision of a freeze dried stool samples before and after spiking, expressed as CV (n=3) 
 
 
Table 4.13. Recovery of a spiked (0.2 µg and 10 µg) stool samples that was refluxed in ethanol prior to derivatisation 
 
Although the results indicate some improvement compared to the values obtained 
without reflux, the precision and accuracy are still not satisfactory. 
 
 
 
  
 CV (n=3) 
 CA CDCA DCA LCA UDCA 
no spike 113 - 12 5 122 
spike 0.2 22 21 11 4 5 
spike 10 18 47 16 6 4 
 % recovery 
Samples CA CDCA DCA LCA UDCA 
spike 0.2 11,95 662,82 332,73 728,71 182,53 
spike 10 58,85 63,12 163,48 139,12 108,16 
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5.1. GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The aim of the present study was to develop and validate a reliable protocol to analyse 
bile acids in faecal samples. The five most prominent bile acids were selected to develop the 
chromatographic method. Baseline separation was achieved using an apolar 100% polysiloxane 
column. Bile acids need to be derivatised at the carboxyl function and hydroxyl functions to 
render them sufficiently volatile for analysis using gas chromatography. Esterification of the 
carboxyl function with butanol proceeded optimally in the presence of HCl 12N and heating for 
2 h at 60°C. The most appropriate silylating reagent was HMDS+TMCS+Pyridine (3:1:9) and 
heating for 30 min at 55°C was sufficient to obtain adequate derivatisation.  
When moving from standard solutions to faecal samples, an additional sonication step 
for 90 min proved to be efficient in increasing the peak area of the derivatised bile acids.  
The validation of the method using standard bile acid solutions resulted in good 
intraday and interday precision and accuracy. The limit of detection (LOD) and limit of 
quantification (LOQ) values were sufficiently low to allow quantification of the bile acids in 
faecal samples. Nevertheless, precision and accuracy in faecal samples (either freeze dried 
stool samples or dried faecal water) were unacceptably low which might be attributed to matrix  
effects hindering appropriate derivatisation and extraction of the bile acids.  
Solubilisation of the bile acids by refluxing the faecal samples in ethanol prior to 
derivatisation improved the precision and accuracy of the measurement but not to a level t hat 
can be considered as appropriate.  
To further develop this method into a suitable and valid method for faecal bile acid 
measurement, additional efforts need to be done to improve the sample preparation and clean 
up the faecal samples prior to derivatisation. An alternative solution might be to switch the 
analytical platform used and move to LC-MS/MS. In this case, no prior derivatisation of the 
samples is required although some clean-up and upconcentration of the faecal samples might 
be necessary.  
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ANNEXES 
A. Average and Standard Deviation values for faecal samples that reflect the 
intraday precision  
 
The following Tables (Table A.1 and Table A.2) show the average and standard 
deviation (SD) of the faecal samples.  
 
 
Table A.1. Average values of faecal samples using the optimized GC-MS method 
 
 
 
 
 
Samples CA CDCA DCA LCA UDCA 
S1  0.018 0.106 7.218 10.681 0.009 
S1 spike 1 0.120 0.142 7.315 9.784 0.069 
S1 spike 10 0.933 0.587 7.239 12.836 0.713 
S2  3.310 0.593 1.546 0.684 0.154 
S2 spike 1 5.591 1.074 2.527 0.921 0.237 
S2 spike 10 6.621 1.410 5.234 3.269 0.992 
S3  37.052 7.782 0.016 0.047 2.430 
S3 spike 1 35.409 7.322 0.306 0.277 2.591 
S3 spike 10 23.152 4.754 2.349 2.412 3.243 
FW1 0.005 0.010 0.311 0.468 0.079 
FW1 spike 1 0.014 0.013 0.352 0.849 0.150 
FW1 spike 10 0.092 0.058 1.017 3.642 0.911 
FW2 26.953 1.445 0.005 0.011 0.002 
FW2 spike 1 27.665 1.561 0.301 0.216 0.062 
FW2 spike 10 30.251 2.294 3.789 2.448 0.793 
FW3 4.962 0.553 0.462 0.158 0.074 
FW3 spike 1 4.800 0.485 0.775 0.402 0.137 
FW3 spike 10 4.368 0.589 2.449 2.838 0.926 
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Table A.2. Standard Deviation of faecal samples using the optimized GC-MS method 
 
 Samples CA CDCA DCA LCA UDCA 
S1  0.002 0.041 0.814 0.349 0.001 
S1 spike 1 0.029 0.016 1.131 0.283 0.002 
S1 spike 10 1.047 0.765 5.500 0.593 0.173 
S2  1.300 0.230 0.357 0.034 0.015 
S2 spike 1 0.489 0.089 0.094 0.043 0.011 
S2 spike 10 0.738 0.170 0.787 0.107 0.022 
S3  0.337 0.669 0.003 0.008 0.273 
S3 spike 1 5.718 1.698 0.026 0.017 0.118 
S3 spike 10 19.650 4.018 1.747 0.289 0.146 
FW1 0.001 0.001 0.041 0.059 0.001 
FW1 spike 1 0.009 0.006 0.126 0.214 0.005 
FW1 spike 10 0.053 0.023 0.469 0.621 0.062 
FW2 2.685 0.228 0.001 0.002 0.001 
FW2 spike 1 2.141 0.205 0.012 0.009 0.002 
FW2 spike 10 0.266 0.062 0.053 0.014 0.007 
FW3 6.887 0.745 0.431 0.023 0.004 
FW3 spike 1 2.661 0.257 0.293 0.021 0.018 
FW3 spike 10 1.838 0.226 0.699 0.098 0.042 
